Education
About Us
Working with TipRanks
Follow Us
Aquestive Therapeutics (AQST)
NASDAQ:AQST
Earnings Data
Report Date
May 06, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.17Last Year’s EPS
-0.17Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 05, 2025
|% Change Since: -5.38%
|Next Earnings Date:May 06, 2025
Earnings Call Sentiment|Neutral
Aquestive Therapeutics demonstrated significant progress in advancing its lead asset Anaphylm towards FDA approval and preparing for international expansion. However, challenges include decreased quarterly revenue, increased net loss, and legal setbacks for Libervant. The sentiment is mixed with balanced highlights and lowlights.Company Guidance
During the call, Aquestive Therapeutics provided several key metrics and guidance for the upcoming periods. The company announced that it expects FDA approval for its Anaphylm product in the first quarter of 2026, with the NDA acceptance anticipated in June 2025. They also plan to initiate the AQST-108 Phase 2a clinical trial in the next quarter. Financially, Aquestive reported total revenues of $57.6 million for 2024, up 14% from 2023, but anticipates revenues between $47 million and $56 million for 2025, factoring in potential erosion in Suboxone demand and including Libervant sales for ages 2 to 5. Non-GAAP adjusted EBITDA loss is projected to be $46 million to $53 million for 2025. As of December 31, 2024, the company had cash and cash equivalents of $71.5 million, with an additional $21.4 million raised in February 2025, bringing the pro forma total to approximately $93 million. Aquestive emphasized its commitment to continuing pre-commercial preparations for Anaphylm and the commercialization of Libervant, even amid ongoing legal challenges.FDA Filing for Anaphylm
Aquestive Therapeutics has begun the filing process with the FDA for approval of Anaphylm, an epinephrine sublingual film. The NDA acceptance is expected in June 2025, with a potential launch in Q1 2026.
Pediatric Study Progress for Anaphylm
The pediatric study for Anaphylm has progressed as expected, with data supporting the product label to mirror existing EpiPen auto injector parameters.
International Expansion Plans
Aquestive is preparing to submit applications for Anaphylm in the EU, UK, and Canada, exploring ex-U.S. partnerships for commercialization.
Development of AQST-108
Aquestive plans to open an IND for AQST-108, a topical gel formulation of epinephrine, with a Phase 2a trial expected in the next quarter.
Revenue Growth in 2024
Total revenues increased by 14% to $57.6 million for the full year 2024, driven by increases in license and royalty revenue.
---
AQST Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
AQST Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 05, 2025 | $2.79 | $2.58 | -7.53% |
| Nov 04, 2024 | $5.15 | $4.76 | -7.57% |
| Aug 06, 2024 | $3.40 | $3.43 | +0.88% |
| May 07, 2024 | $3.38 | $3.08 | -8.88% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Aquestive Therapeutics (AQST) report earnings?
Aquestive Therapeutics (AQST) is schdueled to report earning on May 06, 2025, TBA Not Confirmed.
What is Aquestive Therapeutics (AQST) earnings time?
Aquestive Therapeutics (AQST) earnings time is at May 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AQST EPS forecast?
AQST EPS forecast for the fiscal quarter 2025 (Q1) is -0.17.
---